

[Products](#) / [Stents: Coronary](#) / SYNERGY™

SYNERGY™

Monorail

Everolimus-Eluting Platinum Chromium Coronary Stent System

Exceptional Deliverability

SYNERGY™ 48 mm

Early Healing

Clinical Outcomes



The SYNERGY™ BP Stent features an innovative delivery system for Exceptional Deliverability.

Zero in on Safety. Heal With Confidence.

The SYNERGY™ Bioabsorbable Polymer Stent comes with Synchrony bioabsorbable polymer coating on the abluminal side. Polymer is gone when no longer needed, shortly after completion of drug elution at 3 months.

Providing **Suppression** of neointimal growth at the arterial wall & **Promotion** of healing inside the lumen.

The SYNERGY™ Stent System is equipped with a delivery system having new Laser-cut hypotube technology which provides exceptional deliverability by improving pushability and trackability.

Explore

[Exceptional Deliverability](#)

[SYNERGY™ 48 Mm](#)

[Early Healing](#)

[Clinical Outcomes](#)

[Ordering Information](#)

Exceptional Deliverability

Synergy™ stent system comes with New laser-cut Hypotube technology having ~300 cuts over 100 mm length. It Extends into midshaft to exit port to improve pushability. Additional length maintains midshaft flexibility.


Laser-cut hypotube provides exceptional deliverability by improving pushability and trackability.



[Read more >](#)

SYNERGY™ 48 mm

Long lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time.



[Read more >](#)



[Careers](#)

Abluminal bioabsorbable polymer (BP) application

Emphasizes suppression of neointimal growth at the arterial wall while promoting healing inside the vessel.

Thin, rounded struts

Stents with thinner strut designs have been shown to heal faster than thicker strut stents.¹



Fast-absorbing bioabsorbable polymer

Polymer is gone when it is no longer needed, shortly after the drug is completely eluted.²

Optimal drug release

Market-leading Everolimus drug is completely eluted with optimal kinetics at 3 months.

[Read more >](#)

Clinical Outcomes

The SYNERGY™ BP Stent demonstrates consistently low stent thrombosis rates in over 18,000 patients across 9 studies


ARC ST (Def) Rates for the SYNERGY™ BP Stent¹⁷

Low late and very late ST rates across multiple trials.

	SWEET Registry	Fribourg Experience	Belfast Experience	EVOLVE II Trial	EVOLVE Trial	EVOLVE China Trial	EVOLVE II QCA Study	SCAAR Registry	BIO-RESORT Trial
N:	820	671	185	846	94	205	100	14,979 [§]	1,172
Acute ≤ 1-day	1.5%	0.3%	0%	0.2%	0%	0%	0%	0.08% [§]	0.1%
Sub-acute 2–30-days	0.1%	0.3%	0%	0%	0%	0%	0%	0.02% [§]	0.1%
Late 30 days–1-year	0.1%	0.1%	0%	0%	0%	0%	0%	0.20% [§]	0.2%
Very Late Beyond 1-year			0%	0.2%	0%			0.10% [§]	0.3%


[Read more >](#)

Ordering Information



SYNERGY™ BP Stent, now available in 48mm

STENT LENGTH (mm)



[Careers](#)

Early Healing

Find out how synchronous drug elution and polymer absorption enables early healing.



Patients should follow healthcare professional's guidance for utilization of Dual Anti-Platelet Therapy (DAPT) following stent implantation. Prior to use, please review full device DFU for indications, contraindications, warnings, precautions, adverse events and operator instructions.

[!\[\]\(d66ff64371a51729ac8c1cdaa685ba6f_img.jpg\)](#) [!\[\]\(0f31ebba7abcd47777e178db26f29705_img.jpg\)](#) [!\[\]\(63ea948177b1bcc486b2b76d20d5fb69_img.jpg\)](#) [!\[\]\(886f7dced1265a6d438eca0881817b40_img.jpg\)](#)

[Privacy Policy](#) [Terms of Use](#) [Copyright Notice](#)